name: | SusoctocogAlfa |
ATC code: | B02BD14 | route: | intravenous |
n-compartments | 1 |
Susoctocog alfa is a recombinant, factor VIII (FVIII) replacement therapy derived from human cell-line, used for the treatment and prevention of bleeding episodes and perioperative management in patients with congenital hemophilia A who have developed inhibitors to FVIII. It is used as a bypassing agent and is currently approved for clinical use in this indication.
Pharmacokinetic parameters for susoctocog alfa are reported in adult hemophilia A patients with FVIII inhibitors.